Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
Status unconfirmed · Phase 2
Conditions studied: Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction
In brief
Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced gastric cancer.
Key facts
- Study ID
- NCT01095120
- Run by
- Genta Incorporated
- People needed
- 27
- Starts
- 2010-03-01
- Expected to finish
- 2012-10-01
- Last updated by the study team
- 2012-03-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Northwestern Medical Faculty Foundation — Chicago, Illinois, United States
- Abramson Cancer of the University of Pennsylvania at Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania, United States
- The University of Texax MD Anderson Cancer Center — Houston, Texas, United States
- Severance Hospital, Yonsei University Health System — Seoul, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.